Skip to main content
AAN.com
Views & Reviews
August 28, 2013

Migraine and structural changes in the brain
A systematic review and meta-analysis

October 1, 2013 issue
81 (14) 1260-1268

Abstract

Objective:

To evaluate the association between migraine without aura (MO) and migraine with aura (MA) and 3 types of structural brain abnormalities detected by MRI: white matter abnormalities (WMAs), infarct-like lesions (ILLs), and volumetric changes in gray and white matter (GM, WM) regions.

Methods:

PubMed as well as the reference lists of identified studies and reviews were used to identify potentially eligible studies through January 2013. Candidate studies were reviewed and eligible studies were abstracted. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated for WMAs and ILLs.

Results:

Six population-based and 13 clinic-based studies were identified. The studies suggested that structural brain changes, including WMAs, silent ILLs, and volumetric changes in GM and WM regions, were more common in migraineurs than in control groups. The results were strongest for MA. The meta-analysis of WMAs showed an association for MA (OR 1.68; 95% CI 1.07–2.65; p = 0.03) but not for MO (OR 1.34; 95% CI 0.96–1.87; p = 0.08). The association of ILLs was greater for MA (OR 1.44; 95% CI 1.02–2.03; p = 0.04) than for MO, but no association was found for MA (p = 0.52) and MO (p = 0.08) compared to controls.

Conclusion:

These data suggest that migraine may be a risk factor for structural changes in the brain. Additional longitudinal studies are needed to determine the differential influence of migraine without and with aura, to better characterize the effects of attack frequency, and to assess longitudinal changes in brain structure and function.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (appendices.doc)
File (bashir_1260.pdf)
File (figures.pdf)
File (images-appendices.doc)
File (table_e-1.docx)

REFERENCES

1.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004;24(suppl 1):1–151.
2.
Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population: a prevalence study. J Clin Epidemiol 1991;44:1147–1157.
3.
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646–657.
4.
Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R. Secular changes in health care utilization and work absence for migraine and tension-type headache: a population based study. Eur J Epidemiol 2005;20:1007–1014.
6.
Moschiano F, D’Amico D, Di Stefano M, Rocca N, Bussone G. The role of the clinician in interpreting conventional neuroimaging findings in migraine patients. Neurol Sci 2007;28:S114–S117.
7.
Fazekas F, Koch M, Schmidt R, et al. The prevalence of cerebral damage varies with migraine type: an MRI study. Headache 1992;32:287–291.
8.
Rovaris M, Bozzali M, Rocca MA, Colombo B, Filippi M. An MR study of tissue damage in the cervical cord of patients with migraine. J Neurol Sci 2001;183:43–46.
9.
Rocca MA, Colombo B, Inglese M, Codella M, Comi G, Filippi M. A diffusion tensor magnetic resonance imaging study of brain tissue from patients with migraine. J Neurol Neurosurg Psychiatry 2003;74:501–503.
10.
Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004;291:427–434.
11.
Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Brain Stem and cerebellar hyperintense lesions in migraine. Stroke 2006;37:1109–1112.
12.
Degirmenci B, Yaman M, Haktanir A, Albayrak R, Acar M. Cerebral and cerebellar ADC values during a migraine attack. Neuroradiology 2007;49:419–426.
13.
Kurth T, Mohamed S, Maillard P, et al. Headache, migraine, and structural brain lesions and function: population based Epidemiology of Vascular Ageing-MRI study. BMJ 2011;342:c7357.
14.
Palm-Meinders IH, Koppen H, Terwindt GM, et al. Structural brain changes in migraine. JAMA 2012;308:1889–1897.
15.
Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine: the population-based MRI CAMERA study. Brain 2005;128:2068–2077.
16.
Scher AI, Gudmundsson LS, Sigurdsson S, et al. Migraine headache in middle age and late-life brain infarcts. JAMA 2009;301:2563–2570.
17.
Rocca MA, Ceccarelli A, Falini A, et al. Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke 2006;37:1765–1770.
18.
Dasilva AFM, Granziera C, Tuch DS, Snyder J, Vincent M, Hadjikhani N. Interictal alterations of the trigeminal somatosensory pathway and periaqueductal gray matter in migraine. Neuroreport 2007;18:301–305.
19.
Schmidt-Wilcke T, Gänβbauer S, Neuner T, Bogdahn U, May A. Subtle grey matter changes between migraine patients and healthy controls. Cephalalgia 2008;28:1–4.
20.
Valfré W, Rainero I, Bergui M, Pinessi L. Voxel-based morphometry reveals gray matter abnormalities in migraine. Headache 2008;48:109–117.
21.
Kim JH, Suh SI, Seol HY, et al. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia 2008;28:598–604.
22.
Schmitz N, Admiraal-Behloul F, Arkink EB, et al. Attack frequency and disease duration as indicators for brain damage in migraine. Headache 2008;48:1044–1055.
23.
Schmitz N, Arkink EB, Mulder M, et al. Frontal lobe structure and executive function in migraine patients. Neurosci Lett 2008;440:92–96.
24.
Jin C, Yuan K, Zhao L, et al. Structural and functional abnormalities in migraine patients without aura. NMR Biomed 2013;26:58–64.
25.
Lipton RB, Pan J. Is migraine a progressive brain disease? JAMA 2004;291:493–494.
26.
Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 2009;72(suppl 1):S3–S7.
27.
Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999;53:537–542.
28.
Matharu MS, Good CD, May A, Bahra A, Goadsby PJ. No change in the structure of the brain in migraine: a voxel-based morphometric study. Eur J Neurol 2003;10:53–57.
29.
Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683–1689.
30.
Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter hyperintensities. Neurology 2008;71:804–811.
31.
Dinia L, Bonzano L, Albano B, et al. White matter lesions progression in migraine with aura: a clinical and MRI longitudinal study. J Neuroimaging 2013;23:47–52.
32.
Jefferson AL, Tate DF, Poppas A, et al. Lower cardiac output is associated with greater white matter hyperintensities in older adults with cardiovascular disease. J Am Geriatr Soc 2007;55:1044–1048.
33.
Shrestha I, Takahashi T, Nomura E, et al. Association between central systolic blood pressure, white matter lesions in cerebral MRI and carotid atherosclerosis. Hypertens Res 2009;32:869–874.
34.
Trauninger A, Leél-Össy E, Kamson DO, et al. Risk factors of migraine-related brain white matter hyperintensities: an investigation of 186 patients. J Headache Pain 2011;12:97–103.
35.
Ueno Y, Shimada Y, Tanaka R, et al. Patent foramen ovale with atrial septal aneurysm may contribute to white matter lesions in stroke patients. Cerebrovasc Dis 2010;30:15–22.
36.
Spence JD, Wong DG, Melendez LJ, Nichol PM, Brown JD. Increased prevalence of mitral valve prolapsed in patients with migraine. Can Med Assoc J 1984;131:1457–1460.
37.
Vahedi K, Chabriat H, Levy C, Joutel A, Tournier-Lasserve E, Bousser MG. Migraine with aura and brain magnetic resonance imaging abnormalities in patients with CADASIL. Arch Neurol 2004;61:1237–1240.
38.
Hirano M, Ricci E, Koenigsberger MR, et al. MELAS: an original case and clinical criteria for diagnosis. Neuromuscul Disord 1992;2:125–135.
39.
Filippi M, Rocca MA, De Stefano N, et al. Magnetic resonance techniques in multiple sclerosis. Arch Neurol 2011;68:1514–1520.
40.
Rossato G, Adami A, Thijs VN, et al. Cerebral distribution of white matter lesions in migraine with aura patients. Cephalalgia 2010;30:855–859.
41.
Rist PM, Dufouil C, Glymour MM, Tzourio C, Kurth T. Migraine and cognitive decline in the population-based EVA study. Cephalalgia 2011;31:1291–1300.
42.
Buyck JF, Dufouil C, Mazoyer B, et al. Cerebral white matter lesions are associated with the risk of stroke but not with other vascular events: The 3-City Dijon study. Stroke 2009;40:2327–2331.
43.
Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004;62:563–568.
44.
Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan study. Stroke 2002;33:21–25.
45.
Vermeer SE, Longstreth WT, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007;6:611–619.
46.
Kurth T, Tzourio C. Migraine and cerebral infarct-like lesions on MRI: an observation, not a disease. JAMA 2009;301:2594–2595.
47.
Sándor PS, Mascia A, Seidel L, de Pasqua V, Schoenen J. Subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements. Ann Neurol. 2001;49:668–672.
48.
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215–1222.
49.
Schmidt-Wilcke T, Leinisch E, Straube A, et al. Gray matter decrease in patients with chronic tension type headache. Neurology 2005;65:1483–1486.
50.
Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001;41:629–637.
51.
Kruit MC, Launer LJ, Overbosch J, van Buchem MA, Ferrari MD. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia 2008;29:351–359.
52.
Guidelines from the American Academy of Neurology and US Headache Consortium: neuroimaging in patients with nonacute headache. Available at: http://tools.aan.com/professionals/practice/pdfs/gl0088.pdf. Accessed November 28, 2011.

Information & Authors

Information

Published In

Neurology®
Volume 81Number 14October 1, 2013
Pages: 1260-1268
PubMed: 23986301

Publication History

Received: January 9, 2013
Accepted: July 1, 2013
Published online: August 28, 2013
Published in print: October 1, 2013

Permissions

Request permissions for this article.

Disclosure

A. Bashir reports no disclosures. R. Lipton receives research support from the NIH [PO1 AG03949 (Program Director), RO1AG025119 (Investigator), RO1AG022374-06A2 (Investigator), RO1AG034119 (Investigator), RO1AG12101 (Investigator), K23AG030857 (Mentor), K23NS05140901A1 (Mentor), and K23NS47256 (Mentor)], the National Headache Foundation, and the Migraine Research Fund; serves on the editorial board of Neurology®; has reviewed for the NIA and NINDS; holds stock options in eNeura Therapeutics; and serves as consultant, advisory board member, or has received honoraria from Allergan, American Headache Society, Autonomic Technologies, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, MAP, Merck, Nautilus Neuroscience, Novartis, NuPathe, Pfizer, and Vedanta. Dr. S. Ashina received honoraria for lecturing from Allergan and Neurogesx and is a consultant for Depomed. Dr. M. Ashina is an associate editor of Cephalalgia and is a consultant or scientific adviser for Autonomic Technologies, Inc., Allergan, Amgen, and Alder. Go to Neurology.org for full disclosures.

Study Funding

Supported by the Lundbeck Foundation and the Novo Nordisk Foundation.

Authors

Affiliations & Disclosures

Asma Bashir, MD
From the Danish Headache Center and Department of Neurology (A.B., M.A.), Glostrup Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Copenhagen, Denmark; Montefiore Headache Center (R.B.L.), Department of Neurology, Albert Einstein College of Medicine, Bronx; and Headache Program (S.A.), Department of Pain Medicine and Palliative Care, Department of Neurology, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Richard B. Lipton, MD
From the Danish Headache Center and Department of Neurology (A.B., M.A.), Glostrup Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Copenhagen, Denmark; Montefiore Headache Center (R.B.L.), Department of Neurology, Albert Einstein College of Medicine, Bronx; and Headache Program (S.A.), Department of Pain Medicine and Palliative Care, Department of Neurology, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY.
Disclosure
Scientific Advisory Boards:
1.
Allergan, e-Neura, Merck
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
American Headache Society, Cognimed, Diamond Headache Clinic Research, Market Force Communications, Merck, Talley Management
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Oxford University Press; Baxter Publishing
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Allergan, Autonomic Technologies, Boston Scientific, CoLucid, GlaxoSmithKline,Novartis, NuPathe
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Bristol Myers Squibb Eaarly Detection of Alzheimer's Disease June 2010 - present Vedanta Research Migraine epidemiology and Progression June 2010 - present Boston Scientific Occipital Nerve Stimulation in Migraine March 2013 - present ElectroCore Vagal Nerve Stimulation for Migraine and Cluster May 2013 Novartis Sleep and Migraine September 2012 - present Allergan Botox in Migraine April 2012 - present Allergan Chronic Migraine Epidemiology and Outcome Study January 2012 - present
Research Support, Government Entities:
1.
P01 AG03949 4/1/11-3/31/16 Einstein Aging Study Role: Principle Investigator 1KL2RR025749 07/01/09-06/30/13 Clinical and Translational Science Award (CTSA) Research Career Development Award Role: Primary Mentor R01AG022374 8/1/10-7/31/15 Biomarkers in Early Alzheimer's Disease Role: Investigator R01AG034119 8/1/10-7/31/15 Two Preclinical Latent Scores to Predict Occurrence of DAT Role: PI, Einstein Site R01AG012101 9/15/10-7/31/15 MRI Progression Markers of Cognitive Decline in the Elderly Role: PI, Einstein Site 1R01AG039409-01 Stress, Unconstructive Repetitive Thought & Cognitive Aging 4/1/11-3/31/16 Role: PI, Einstein Site 1R01AG038651-01A1 Role of impaired cognitive states & risk factors in conversion to mixed dementias 9/1/11-8/31/16 Role: PI, Einstein Site 1U10NS077308- 01 9/30/11-8/31/18 Einstein Center for Excellence for Clinical Trials in Neuroscience Role: PI NIH 4/1/12-3/31/17 Behavioral Weight Loss as a Treatment for Migraine in Obese Women Role: Investigator NIH 1R01AG042595 - 01A1 Stress, cognition, repetitive unconstructive thoughts and inflammatory markers Role: Investigator
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
S & L Marx Foundation Alzheimer's Research
Stock/stock Options/board of Directors Compensation:
1.
Minster Pharma
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sait Ashina, MD
From the Danish Headache Center and Department of Neurology (A.B., M.A.), Glostrup Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Copenhagen, Denmark; Montefiore Headache Center (R.B.L.), Department of Neurology, Albert Einstein College of Medicine, Bronx; and Headache Program (S.A.), Department of Pain Medicine and Palliative Care, Department of Neurology, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
speaker honoraria from Allergan and NeurogesX
Editorial Boards:
1.
1. Visiting Associate Editor, Journal of Headache and Pain 2012-now 2. Associate Editor, Neurology Reviews, 2010-now
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Assistant Professor of Neurology and Anesthesiology, Beth Israel Medical Center, Albert Einstein College of Medicine
Consultancies:
1.
Have served as a consultant on advisory board of Depomed
Speakers' Bureaus:
1.
On speakers bureau for Allergan and Nautilus Neurosciences
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Messoud Ashina, MD, PhD
From the Danish Headache Center and Department of Neurology (A.B., M.A.), Glostrup Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Copenhagen, Denmark; Montefiore Headache Center (R.B.L.), Department of Neurology, Albert Einstein College of Medicine, Bronx; and Headache Program (S.A.), Department of Pain Medicine and Palliative Care, Department of Neurology, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY.
Disclosure
Scientific Advisory Boards:
1.
Dr. Ashina is a consultant and/or scientific adviser for the ATI, Allergan, Amgen and Alder.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
2009: Dr. Messoud Ashina has received support from Merck to participate at the International Headache Society Congress
Editorial Boards:
1.
Massoud Ashina is an associate editor of Cephalgia Member of advisory board: The Journal of Headache and Pain
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
Honoraria for lecturing from Pfizer, GlaxoSmithKline, Norpharma, AstraZeneca and Allergans
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to Dr. M. Ashina: [email protected]
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Dr. Bashir and Dr. M. Ashina conceived and designed (including search strategies) the review. Dr. Bashir did the literature search and wrote the first and subsequent drafts of the manuscript. Dr. S. Ashina conducted the meta-analysis. Dr. Lipton, Dr. S. Ashina, and Dr. M. Ashina participated in critical revision and writing of the article. All authors have seen and approved the final version.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Specifically formulated ketogenic, low carbohydrate, and carnivore diets can prevent migraine: a perspective, Frontiers in Nutrition, 11, (2024).https://doi.org/10.3389/fnut.2024.1367570
    Crossref
  2. Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics, Frontiers in Molecular Neuroscience, 17, (2024).https://doi.org/10.3389/fnmol.2024.1355281
    Crossref
  3. Reviewing migraine-associated pathophysiology and its impact on elevated stroke risk, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1435208
    Crossref
  4. Comparison of patients with chronic and episodic migraine with healthy individuals by brain volume and cognitive functions, The European Research Journal, (1-15), (2024).https://doi.org/10.18621/eurj.1461935
    Crossref
  5. Association between migraine and the risk of vascular dementia: A nationwide longitudinal study in South Korea, PLOS ONE, 19, 4, (e0300379), (2024).https://doi.org/10.1371/journal.pone.0300379
    Crossref
  6. Analysis of Factors Affecting the Quality of Life of Migraine Patients, Advances in Clinical Medicine, 14, 05, (1563-1568), (2024).https://doi.org/10.12677/acm.2024.1451588
    Crossref
  7. Modulation of temporal and occipital cortex by acupuncture in non-menstrual MWoA patients: a rest BOLD fMRI study, BMC Complementary Medicine and Therapies, 24, 1, (2024).https://doi.org/10.1186/s12906-024-04349-w
    Crossref
  8. Migraine or any headaches and white matter hyperintensities and their progression in women and men, The Journal of Headache and Pain, 25, 1, (2024).https://doi.org/10.1186/s10194-024-01782-7
    Crossref
  9. The glymphatic system in migraine and other headaches, The Journal of Headache and Pain, 25, 1, (2024).https://doi.org/10.1186/s10194-024-01741-2
    Crossref
  10. Migraine and brain structure in the elderly: The Rotterdam Study, Cephalalgia, 44, 9, (2024).https://doi.org/10.1177/03331024241266951
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share